Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
119 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Electrocore (ECOR) is navigating a pivotal year. This article dives into the 2025 earnings landscape, unpacking reven...
A venture-backed biotech startup unveils a plan to collect genomic data from 100 million species to fuel AI drug disc...
New heart health guidelines urge Lp(a) testing for at-risk adults, sending demand for diagnostics higher. This report...
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
A Sydney-based tech founder uses AI to design a bespoke cancer vaccine for his dog, Rosie, signaling a new frontier i...
Biotech stocks rally as late-stage trial data and regulatory milestones boost investor confidence. Analysts say the b...
A biotech stock that sprinted 685% in months drew a sizeable institutional bet as it pressed ahead with two FDA filin...
What Mineralys (MLYS) reported in its 2025 earnings reveals more than numbers. This guide breaks down the quarter, th...
An almost 12% jump in lantheus holdings stock popped last month left investors asking what lit the fuse. This article...